<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04589585</url>
  </required_header>
  <id_info>
    <org_study_id>VV0146</org_study_id>
    <nct_id>NCT04589585</nct_id>
  </id_info>
  <brief_title>Clinical Study of Merlin's DiVeRt - Vascular Reconstruction Device and Delivery System</brief_title>
  <official_title>Merlin's DiVeRt-Vascular Reconstruction Device: a Prospective, Single Arm, Non-randomized, Open Label Study to Assess Safety and Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merlin MD Pte Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merlin MD Pte Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the proposed investigation is to assess the safety and effectiveness of the&#xD;
      Merlin's DiVeRt system for the treatment of intracranial lesions.&#xD;
&#xD;
      Merlin is a manufacturer of Flow- Diverters (FD) for Neurovascular applications. The&#xD;
      technology is based on a microporous polymer membrane which is delivered to the site of&#xD;
      lesion treatment using a metal stent scaffold. The first device in its FD family is the&#xD;
      XCalibur Aneurysm Occlusion Device (AOD) system, which is delivered on a rapid-exchange&#xD;
      balloon catheter which goes in a 6-Fr guide-catheter. The AOD is CE-marked and has been&#xD;
      involved in the treatment of over 70 clinical lesion/aneurysm cases. The same technology is&#xD;
      now being made available in a self-expandable stent platform delivered on a 0.028&quot;&#xD;
      microcatheter. Merlin has performed the required in-silico, in-vitro and in-vivo tests to be&#xD;
      confident of the device performance and now intends to proceed to the human clinical-trials.&#xD;
      DiVeRt (Interventional) is a non CE mark device. The device is under clinical trial phase.&#xD;
      The competent authority submission for the study has been completed in Spain, Turkey and&#xD;
      Hungary.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will recruit patients with intracranial aneurysm (IA) or a lesion located in the&#xD;
      anterior or posterior circulation. The analyses of the data from this safety and feasibility&#xD;
      study will be descriptive.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all serious adverse events assessed, clinically or angiographically</measure>
    <time_frame>3 months</time_frame>
    <description>Serious Adverse events will be evaluated as device-related, procedure-related, or unrelated to the procedure or the device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of unsuccessful Divert placement</measure>
    <time_frame>3 months</time_frame>
    <description>Incidence of unsuccessful Divert placement leading to, or with the potential of leading to, adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aneurysm Occlusion Grading: MRRC scale</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation of degree of aneurysm occlusion or degree of delayed opacification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-stent stenosis (DSA)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of perforator vessel patency immediately post-implantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Intracranial Aneurysm, Wide Neck Aneurysm, Large Neck Aneurysm, Lesion</condition>
  <arm_group>
    <arm_group_label>DiVeRt treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DiVeRt device to be used in the single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DiVeRt</intervention_name>
    <description>DiVeRt - Vascular Reconstruction Device and Delivery System</description>
    <arm_group_label>DiVeRt treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has provided written informed consent using the IRB/EC-approved consent form&#xD;
             and agrees to comply with protocol requirements.&#xD;
&#xD;
          -  Age 18-80 years.&#xD;
&#xD;
          -  Subject has a target intracranial aneurysm (IA) or a lesion located in the anterior or&#xD;
             posterior circulation.&#xD;
&#xD;
          -  Subject has a target IA with a wide or large neck aneurysm or a lesion. The aneurysm&#xD;
             type includes saccular, fusiform, dissecting or blister shapes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery in the last 30 days.&#xD;
&#xD;
          -  History of irreversible bleeding disorder and/or subject presents with signs of active&#xD;
             bleeding.&#xD;
&#xD;
          -  NIH Stroke Scale ( NIHSS) greater than or equal to 4&#xD;
&#xD;
          -  Any known contraindication to treatment with flow diverters.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Participating in another clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sweta Mrs Singh, Masters</last_name>
    <phone>68920020</phone>
    <phone_ext>135</phone_ext>
    <email>ssingh@merlinmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vall De Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro Dr Tomasello</last_name>
      <phone>(+34) 93 489 30 00</phone>
      <email>alejandrotomasello@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>David Dr Hernandez</last_name>
      <phone>(+34) 93 489 30 00</phone>
      <email>dhm050780@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

